[Brachytherapy for prostate neoplasms].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Shiro Saito.
Explore the source record for details and available documents.
Reports on patients with systemic amyloidosis-associated plasma cell dyscrasia (PCD) who have multiple endocrine tumors are very rare. Here we describe such a case. The patient was a 74-yr-old man with amyloid light-chain (AL) amyloidosis-associated PCD who had a null-cell adenoma of the pituitary and a latent papillary carcinoma of the thyroid gland. as well as a tubular adenoma of the sigmoid colon. The amyloid protein deposits reacted with the antibody to the n-immunoglobulin light chain. Since PCD by itself may be a risk factor for the development of subsequent neoplasms, the careful clinical evaluation of PCD patients is recommended.
We examined the immunohistochemical localization of activin A/erythroid differentiation factor (EDF) in the pancreases of normal and diabetic rats with insulin-dependent diabetes mellitus or noninsulin-dependent diabetes mellitus to elucidate how activin A/EDF modulates insulin secretion. In both the normal and the diabetic pancreas, all of the cells staining with antirecombinant human (rh) activin A/EDF antiserum were insulin-producing B-cells, and they gradually decreased in number with the development of diabetic changes in both types of diabetic rats. No rh activin AIEDF immunoreactivity was detected in A-, D-, or pancreatic polypeptide (PR) cells in the islets, or in the exocrine cells. The in situ hybridization (ISH) method showed that activin A/EDF mRNA is localized in activin A/EDF-positive cells. These data indicated that activin A/EDF localizes in insulin-producing B-cells of normal and diabetic pancreases, and may act as an autocrine modulator of insulin secretion.